NHI coverage extended to Visudyne, a macular degeneration therpay.

Novartis Korea's Visudyne (verteporfin), a photodynamic therapeutic drug for macular degeneration, took the government approval for the NHI coverage effective from July 1, 2005 specifically for 1) the patients suffering from macular degeneration, 2) the patients who showed enlarged and new eye blood vessels or new bleeding in 2 months upon its first finding, and 3) the patients who showed a new...